EGFR and non-small cell lung carcinoma: Osimertinib, as the third-generation EGFR TKI drug, has shown excellent efficacy in animal models and NSCLC patients with EGFR T790M mutation, with an ORR of 70% and a median PFS of 9.9 months (Jänne et al., 2015; Mok et al., 2017).